Fisetin for Women 50+: Hormonal Aging and Senescence Evidence
Expert Summary
Estrogen suppresses the accumulation of senescent cells by promoting BCL-2-independent apoptosis in aged cells. At menopause, this protective effect is lost, leading to accelerated senescent cell accumulation in fat, bone, and cardiovascular tissue. Fisetin fills part of this gap via its BCL-2-targeting senolytic mechanism.
Key Facts
- Estrogen and senescence: Estradiol maintains expression of pro-apoptotic BCL-2 family members in aging cells. Menopause-associated estrogen loss removes this mechanism, allowing senescent cell accumulation to accelerate 2–3x faster than in pre-menopausal tissue.
- Adipose senescence in menopause: Visceral fat expansion post-menopause is partly driven by senescent preadipocytes that secrete SASP factors disrupting normal fat metabolism. Fisetin specifically targets these adipose senescent cells in animal models.
- Bone protection: Osteoclast-senescent cell interactions drive bone loss in post-menopausal osteoporosis. Clearance of senescent osteocytes with senolytics (including fisetin) reduces bone loss in ovariectomized mice — a validated menopause model.
- Cardiovascular senescence: Endothelial senescence accelerates post-menopause, contributing to arterial stiffness and hypertension. Fisetin clears senescent endothelial cells in animal studies and reduces vascular stiffness biomarkers.
- Hormonal safety: Fisetin has mild phytoestrogen-like activity in vitro but at supplemental doses, estrogenic effects in vivo appear negligible. Unlike isoflavones, fisetin is not considered a clinically significant phytoestrogen.
- Dosing for women 50+: The same 20 mg/kg protocol applies. Monthly cycling may be more appropriate given the accelerated senescent cell reaccumulation rate post-menopause.
Recommended Products
Frequently Asked Questions
Can fisetin replace hormone replacement therapy (HRT)?
No. HRT acts through estrogen receptor signaling with systemic hormonal effects. Fisetin is a senolytic with anti-inflammatory properties. They address different aspects of aging; some practitioners combine both with physician guidance.
Is there a specific dose for post-menopausal women?
The same 20 mg/kg protocol applies. Monthly (vs quarterly) cycling is more commonly recommended for post-menopausal women given the faster senescent cell reaccumulation rate.
Does fisetin help with hot flashes or menopausal symptoms?
Limited evidence exists for direct symptomatic relief of hot flashes. The anti-inflammatory effects may reduce some menopausal symptoms indirectly, but fisetin is not a first-line treatment for menopausal symptoms.
Scientific References
- Farr JN et al. Targeting cellular senescence prevents age-related bone loss in mice. Nature Medicine. 2017. PMID: 28825716
- Zhu Y et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging. 2017. PMID: 28900009